Satellite Symposia Programme

Saturday 15 April -13:30 – 15:00 BST

Organised by UCB Biopharma SRL

BMD and clinical decision making in osteoporosis: Are we exploiting the full potential?

Meeting Room: Room 3AB

13:30–13:35 Welcome and introduction
Polyzois Makras (Greece)
13:35–13:55 Reappraisal of surrogate markers in osteoporosis: A focus on BMD*
13:55–14:15 BMD assessment in clinical decision-making: Current and potential applications*
14:15–14:40 Optimising gains in BMD: What does ‘good’ look like and how do we get there?

*Insights from
Richard Eastell (UK) and Bente Langdahl (Denmark) 

with discussion facilitated by
Polyzois Makras (Greece)

Q&A/faculty discussion
14:55–15:00 Conclusions and closing remarks
Polyzois Makras (Greece)



Sunday 16 April – 12:15 – 13:15 BST

Inozyme Pharma

Beyond XLH – Mechanisms and Manifestations of Hypophosphatemic Rickets

Meeting Room: Room 3AB 

12:15 – 13:15   This program will review the pathophysiology and clinical presentation of often underrecognized forms of FGF-23 mediated hypophosphatemic rickets, and present strategies for optimizing diagnosis.
Lothar Seefried (Germany)


Sunday 16 April – 14:45 – 15:45 BST

Kyowa Kirin International plc

Staying on the path to long-term treatment success in XLH

This event is intended for healthcare professionals only who are registered for ECTS 2023. This promotional symposium is organised and funded by Kyowa Kirin and will contain data about Kyowa Kirin products.
Draft agenda subject to change. KKI/INT/CYS/0142 I March 2023

Meeting Room: Hall 1B


14:45 Welcome and introductions
Stuart Ralston (United Kingdom)
14:50 The path to improved outcomes: New data supporting a continued treatment approach for adults with XLH
Kassim Javaid (United Kingdom)
15:10 Navigating the path: Achieving optimal patient outcomes in the real world
Stuart Ralston (United Kingdom)
15:25 Q&A and interactive discussion
All speakers
15:40 Summary and close
Stuart Ralston (United Kingdom)



Gedeon Richter

Is it time to challenge the positioning of anabolic therapy in the osteoporosis treatment pathway?

Meeting Room: Room 3AB            


14.45-15.00 First line anabolic treatment – changing the goals of osteoporosis management
Richard Keen (United Kingdom)
15.00-15.15  Anabolics in the sequential treatment of bone fragility
Maria Luisa Brandi (Romania)
15.15-15.30 Practical aspects of anabolic treatment in real life
Peyman Hadji (Germany)
15:30-15.45 Discussion and Q&A
All speakers

Monday 17 April – 14:45 – 15:45 BST

Amgen (Europe) GmbH

Sponsored Meet-the-Expert
Denosumab: Past, Present and Future – Mechanistic Insights

Meeting Room: Room 3AB 

14:45 – 15:45 Denosumab: Past, Present and Future – Mechanistic Insights
Kassim Javaid (UK)